Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study

Kindler, Hedy L. ; Scherpereel, Arnaud ; Calabrò, Luana ; Aerts, Joachim ; Cedres Perez, Susana ; Bearz, Alessandra ; Nackaerts, Kristiaan ; Fennell, Dean Anthony ; Kowalski, Dariusz ; Tsao, Anne S. ; Taylor, Paul ; Grosso, Federica ; Antonia, Scott Joseph ; Nowak, Anna K. ; Ibrahim, Ramy A. ; Taboada, Maria ; Puglisi, Martina ; Stockman, Paul K. ; Maio, Michele

Texto completo disponível

Tissue-based next generation sequencing (NGS) testing in solid tumors: A single-center experience in Malaysia

Ahmad, Azura Rozila ; Toh, Yi Long ; Tan, William ; Wahid, Mohamed Ibrahim A.

Texto completo disponível

Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody

Segal, Neil Howard ; Antonia, Scott Joseph ; Brahmer, Julie R. ; Maio, Michele ; Blake-Haskins, Andy ; Li, Xia ; Vasselli, Jim ; Ibrahim, Ramy A. ; Lutzky, Jose ; Khleif, Samir

Texto completo disponível

Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study

Qin, Shukui ; Fang, Weijia ; Ren, ZhengGang ; Shuangyan, Ou ; Lim, Ho Yeong ; Zhang, Feng ; Choi, Hye Jin ; Tong, Jiandong ; Tao, Min ; Xu, Aibing ; Cheng, Ashley Chi Kin ; Lu, Chang-Hsien ; Chiu, Chang-Fang ; Wahid, Mohamed Ibrahim A. ; Kamble, Shital ; Norquist, Josephine M. ; Zhong, Wen Yan ; Li, Chen ; Chen, Zhendong

Texto completo disponível

Oral mucositis in cancer treatment: Cross-national perspective of oncologists in Asia and Saudi Arabia

Moon, Hanlim ; Wahid, Mohamed Ibrahim A. ; Lin, Jin-Ching ; Cupino, Nonette ; Liu, Edward ; Kang, Jin Hyoung ; Kanagalingam, Jeeve ; Bazarbashi, Shouki ; Moreira, Nicole ; Arumugam, Harsha ; Mueller, Sfefan

Texto completo disponível

A phase II prospective study of selumetinib in children with recurrent or refractory low-grade glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) study

Fangusaro, Jason R. ; Onar-Thomas, Arzu ; Young-Poussaint, Tina ; Wu, Shengjie ; Ligon, Azra H ; Lindeman, Neal Ian ; Banerjee, Anuradha ; Packer, Roger ; Kilburn, Lindsay B. ; Pollack, Ian ; Jakacki, Regina ; Qaddoumi, Ibrahim A. ; Fisher, Paul Graham ; Dhall, Girish ; Baxter, Patricia Ann ; Kreissman, Susan G. ; Doyle, L. Austin ; Smith, Malcolm A. ; Dunkel, Ira J. ; Fouladi, Maryam

Texto completo disponível

Survival of patients with locally advanced triple-negative breast cancer after neoadjuvant platinum-containing chemotherapy: Experience of a single institute

Ibrahim, E. A.

Texto completo disponível

Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

Levis, Mark J ; Hamadani, Mehdi ; Logan, Brent ; Jones, Richard J ; Singh, Anurag K ; Litzow, Mark ; Wingard, John R ; Papadopoulos, Esperanza B ; Perl, Alexander E ; Soiffer, Robert J ; Ustun, Celalettin ; Ueda Oshima, Masumi ; Uy, Geoffrey L ; Waller, Edmund K ; Vasu, Sumithra ; Solh, Melhem ; Mishra, Asmita ; Muffly, Lori ; Kim, Hee-Je ; Mikesch, Jan-Henrik ; Najima, Yuho ; Onozawa, Masahiro ; Thomson, Kirsty ; Nagler, Arnon ; Wei, Andrew H ; Marcucci, Guido ; Geller, Nancy L ; Hasabou, Nahla ; Delgado, David ; Rosales, Matt ; Hill, Jason ; Gill, Stanley C ; Nuthethi, Rishita ; King, Denise ; Wittsack, Heather ; Mendizabal, Adam ; Devine, Steven M ; Horowitz, Mary M ; Chen, Yi-Bin

United States

Sem texto completo

A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B)

Gajjar, Amar J. ; Gururangan, Sridharan ; Qaddoumi, Ibrahim A ; Packer, Roger ; Goldman, Stewart ; Prados, Michael ; Desjardins, Annick ; Fouladi, Maryam ; Takebe, Naoko ; Li, Shaoyi ; Ellison, David W. ; Curran, Tom ; Gilbertson, Richard J. ; Boyett, James M.

Texto completo disponível

Use of progression-free survival (PFS) as an endpoint in advanced non-small cell lung cancer (NSCLC) trials: FDA perspective

Malik, S. M. ; Ibrahim, A. ; Sridhara, R. ; Justice, R. L. ; Pazdur, R.

Texto completo disponível